Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
ISIS CRP Rx and its effects on CRP and other pharmacodynamic measures, versus placebo, in
subjects with active rheumatoid arthritis.